It was the objectiveofthis study to analyse the influence of confounders,such as ethnicity,severity of illness andmethod of testing,inarticlesconcerning the still moot relationship of thrombophilias to adverse pregnancyoutcome(APO). Relevant casecontrol studies were identified using Medline and EMBASE databases between 1966 and 2006. Search termsw erer ecurrent fetal loss,i ntrauterine fetal death,p reeclampsia,H ELLP-syndrome,eclampsia, fetal growth restriction, abruptio placentae, combinedw ith maternal thrombophilias.D ata was extracted from the articlesper subgroup ofAPO regardless of confounder. Thesesubgroups were tested if theyfulfilled the heterogeneity testingc riterion (I 2 >3 5%)t ow eigh thei nfluence of the confounder.Confounders were selected and examined with MantelHaenszel method. Increasedthrombophilia prevalencewas confirmedi nm ost adverse pregnancyo utcomes.Ethnicity,genetic Keywords Thrombophilia,pregnancy,confounders, illnessseverity testing onlyand severityofillness were confounders in the various forms of APO. Strongerr elationshipsb etween factorV Leiden and severityo fd isease were found in 2 nd and 3 rd trimester than 1 st trimester recurrent fetal loss,inp reeclampsia with: blood pressure ≥160/110 mmHgt han ≥140/90 mmHg; proteinuria ≥5grams perday than <5grams;onset before than after2 8w eeks,inf etal growth restriction< 3 rd percentile than <5 th ,than <10 th ,and in earlier occurrence of abruptio placentae than 3 rd trimester.Inc onclusion, reports on the prevalenceo f maternal thrombophiliasa nd APO arei nfluencedb yv arious confounders, which aren ot always appropriatelya nalysed.The differencesw eh avei dentified reflect the differential impact of these confounders.These datae mphasiset he importance of moreuniformresearch.
Introduction
The influence of pregnancyonhaemostasis and vice versa has been of great interest in obstetric medicine.Aclear relationship between non-hereditary factors( antiphospholipid antibodies) and adversepregnancyoutcome has beenpreviouslyconfirmed, providing ap aradigm for the hypothesis that an increased tendencyt oh ypercoagulabilityl eads to pregnancyc omplications (1) (2) (3) (4) (5) (6) .Thereisanongoing proliferation of researchattempting to clarify the association between hereditary thrombophilic disorders, includingantithrombin deficiency, protein Cdeficiency, protein Sd eficiency, activatedp rotein Cr esistance, factor V Leiden mutation, prothrombin gene G20210A mutation and the common polymorphisms (C677T and A1298C) of the gene for methylenetetrahydrofolate reductase( MTHFR), and adverse pregnancyoutcome (APO).
Despiten umerous publications, however, concerning the prevalenceo fs uch inherited thrombophilias in womenw ith APO,t he relationshipr emains moot, while the heterogeneity among studyr esults is undeniable.I nn umerous reviews published with the aim of elucidating the relationship, onlyaf ew have mentioned the possible influenceo fc onfounders such as ethnicity (7) (8) (9) (10) (11) (12) .This reviewwill focusonthe heterogeneity betweenpublished studies with the aim of identifying and comparing confounders, so as to provide aclearer view on the relationships of thrombophilias to APO.
Methods
To study possible causes of heterogeneity in studiesonthrombophiliaand APO,articlesw ere selected pertaining to the varioust hrombophilicd isorders and using APO as an outcome measurement. Identification of relevant case-control studies Case-control studiesw ere identifiedb ys earching the Medline and EMBASE databasesbetween 1966 and November2006 for terms relating to recurrent fetal loss (RFL), intrauterine fetal death (IUD),preeclampsia (PE), HELLP-syndrome, eclampsia, fetal growth restriction (FGR), abruptio placentae (AP)and fetal thrombophilia, combined with antithrombin deficiency, protein Cdeficiency, protein Sdeficiency, activatedprotein Cresistance (APCR),f actor VL eiden mutation (FVL), prothrombin gene G20210A mutation (PGM), hyperhomocysteinemia (Hhcy), methylenetetrahydrofolate reductase (MTHFR)C 677T and A1298C polymorphisms, antiphospholipid antibodies, anticardiolipin antibodies (ACA) and lupus anticoagulant (LAC).
Onlycase-controlstudiespublished in the English language were accepted for meta-analysis. Theirreferences were explored for other publications. Data wasextractedbyfour reviewers (J.I. P. de Vries, J. J. Kalk, N. G. Janssen, W. J. Kist).
The set-up of themeta-analysis followedthreesteps. Firstly, allarticleswere categorized and analyzed per subgroup of APO (RFL, IUD, PE,FGR,AP) in relation to each thrombophilia regardless of confounder.Secondly, these subgroups were testedto seeiftheyfulfilled the heterogeneity testing criterion (I 2 >35%) to weigh the influenceofthe variousconfounders (13) .Finally, articleswere selected whichestablished aclear definition of the researched confounders so as to analysethe influenceofthe variousconfounders on the relationshipbetween thrombophiliasand APO,u sing RevMans oftwarev ersion 4.2.8 with the MantelHaenszel method for combining trials. TheM antel-Haenszel method is astatistical method for adjusting for confounding factorswhen analysing the relationship between adichotomous outcomeand adichotomous risk factor. (55, 59, 60, 65, 70, 80, 83, 84, 87) showedastronger relationship of PE with MTHFR C677Thomozygous (OR1.68: 95% CI 1.37-2.07) than threearticlesonAsian subjects (78, 79, 86) where the relationship was not significant (OR 1.15:9 5% CI 0.76-1.74). Threea rticles usingAfrican subjects (77,8 1, 85 ) also did not demonstrate a significant relationship (OR 1.53:95% CI 0.34-6.94).
Definitionofpotential confounders

Severity of illness
Of the2 4s tudiesa ddressing the relationshipb etween PE and FVL, half used acut-offof≥140/90 mmHg to define PE (55, 56, 59, 61, 62, 65, 67, 69, 70, 72, 74, 76) , and the other half used a cut-offof≥160/110 mmHg to define severe PE (35, 49, 57, 58, 60, 65, 66, 68, 70, 71, 73, 75) . Those studies with the lowercutofffor blood pressure showedaweaker relationship between PE and FVLthan the studies that used more severe hypertension to define the study population. Articles where proteinuria ≥ 5 gramsper 24 hourswas used as acriterion for severe PE (35, 49, 57, 65, 68, 70, 73) showedas tronger relationship of PE with FVL thant hose articles that used proteinuria <5 gramsp er 24 hoursasthe definition (58, 60, 66, 75) .
Of the 19 articles addressing the relationshipbetween PE and MTHFR C677T homozygous, the six studiesthat used ≥160/110 mmHg as ac riterion for definition (35,6 0, 65, 66, 70, 79) showedas tronger relationship (OR 1.77:9 5% CI 1.32-2.38) than that in 13 articles that used aminimum blood pressure of ≥140/90 mmHg to define the diagnosis ( 89-96, 100) , and all nine articles considering FGR and PGM (49, 89-95, 100) were used in ameta-analysis to compare differentincidencesofthe twogenotypesinFGR belowthe 3 rd , the 5 th and the 10 th percentiles. ForFVL, there wasastrongerrelationship with the moreprofounddegrees of FGR, whereas for PGMthe onlysignificant relationship wasseen forFGR <10 th percentile. As econdm eta-analysis wasp erformed,c omparing articles that used other adverse pregnancyoutcomes as an exclusion criterion with thosethat did not, showedastronger relationship of both FVL and PGMwith FGR combined with otherAPO (see Fig. 2 ).
In relation to FGR and gestational age at delivery,one study identified as ignificant association between FVLa nd FGR in womenwho delivered at agestationalage of 22-26 weeks (92). In as econds tudy (89), as ignificantly higher frequencyo f thrombophiliaswas notedinwomen with FGR whodelivered at or after 37 weeks compared with womenwith FGR regardless of gestationala ge. This study did not, however, document which specifict hrombophilias were linked to FGR at particularg estationalages.
Methodoftesting
Of the12articlesonthrombophiliaand APO five articlesused genotyping and functionalt esting and sevenu sedg enotyping only.
In respect of the association between FGRand FVL, the only testing performed in all included articles wasgenotyping. 
Abruptio placentae
Discussion
This is the first studyfocusing on the effect of confoundersinthe analysis of thrombophilia examineda fter APO. The meta-analysesr eveal the confounding influenceo fe thnicity,s everity of diseaseand genotyping alone versusgenotypingand phenotyping combined in all the examinedvarietiesofAPO.
When considering the prevalenceo fg enetic thrombophilia the knowledge of ethnicity will allowadjustment of resultsfor different populations: for example, the high prevalenceofFVL in Caucasians, and especially Israelis, needs to be consideredin relation to the incidenceofrecurrentfetal loss. Theconfounding influenceofethnicity wasnot, however, limitedtoFVL alonebut could also be demonstrated in respecto fM THFR and PGM, both examinedinrelation to preeclampsia.
Also striking wasthe variedinfluenceofthe severity of the disease in thoseforms of APO we could examine.Firstly, gestational age at birth revealed ahigher incidence of FVLinwomenwith recurrent fetal loss in the 2 nd and3 rd trimester than in thosewith recurrent 1 st trimester loss.This is not surprising considering the absenceofafunctional intervillousspace up to 9-10 week's gestationa, i.e. it is highlyunlikely that athromboticevent could cause embryonic lossprior to nine week's gestation.Inpreeclampsia and abruptioplacentae the confounding influence seemstobethe opposite, theearlier thegestationalage at birth the higherthe incidenceofFVL.InFGR both were found:one study described more FVLa tb irth lesst han2 6w eekst hana to ther gestational ages, while another study found moreFVL at delivery beyond 37 weeks compared with delivery at othergestationalages. An explanation could be that, although the aetiology of FGR is varied, alarge part is duet ou tero-placental insufficiency with the sameo rigin (i.e. thrombotic vasculopathy) as forpreeclampsia.
Secondly, the severity in growth restriction showed the same influenceinboth womenwith pregnancies complicated by FGR or preeclampsia;the more severelygrowthrestrictedfetuses or the earlierthe onset of PE, the higher the incidenceofFVL.
Thirdly, the elevation of the blood pressure had confounding influence; the higher the blood pressure,the higher the incidence of FVL.
Fourthly, the degree of proteinuriahad similar confounding influence; the mores evere the proteinuria,t he higher the incidenceofFVL Fifthly, the studiesonFGR that didnot excludeotheradverse pregnancyo utcomes had ah igheri ncidence of thrombophilic factorsFVL and PGMthan those that did. This leads to the suggestion that multiple adverse pregnancyo utcomes mayb er elatedtoahigherincidence of FVL.
Genetic testing without functional testing limits the information on the thrombophilic status of the subjects. This wasfound for FVL and APCRinall forms of adversepregnancyoutcome. From the work of Lachmeyer et al. ( 101) we knowt he limited correlation betweenMTHFR and hyperhomocysteinemia. This strengthens the needtoelucidate the fullthrombophiliastatus of the patient, includingab road spectrum of functional clotting tests (e.g.p roteinsSa nd C, antithrombin and APCR). Since some of these factorsmay be influenced by pregnancy(including the postpartum period), the analysesneed to be performedata suitable time thereafter.
Alimitation of this studyisthe lackofuniformityamong articles, resulting in high heterogeneity. This wase specially the caseinthose articles relating to abruptio placentae, diminishing the powerofthe confounder meta-analysis, sincerelativelyfew articlescould be used in each confounder analysis.
When confoundersw ere analyzed,s ignificant differences becamee vident. To assess the true influenceo fas ingle confounder,every other variable in the comparison should ideally be the same.Inpractice this rarelyhappens.The differencesinORs between the overallmeta-analyses and the relevant confounderbasedmeta-analyses might therefore notbesolelydue to the influence of the investigated confounder.Theydo, however, give an indication of the degree of impact of the variousconfounders and provide an incentive for moreuniformand well-defined research. Forexample, heparin is increasinglyusedfor prophylaxis of pregnancy-associatedm orbidity in pregnant womenw ith thrombophilia (102) . Tworandomisedcontrolled trials on the effect of heparin in womenwith unexplainedfirst and secondtrimesterrecurrentmiscarriages didfind abeneficialeffect (103, 104) .The trial authors, however, did not discuss whether or not the effect wasrelated to thrombophilia,nor did theyconsider if the consequencei st hat even recurrent first trimesterm iscarriages have to be treated. Theuncertaintyabout the role of thrombophiliaishighlightedinthat, although one trial (103) studied womenwith antiphospholipid antibodies(withoutknowledge of other thrombophilic factors), the othertrial (104) found the effect to occur in womeneveninabsenceofantiphospholipidantibodies or other thrombophilia factors. The uncertainty about the consequenceo ft reatment of recurrent first trimesterm iscarriages is increased,inasmuchasboth trials lumped togethertheir data from first and second trimestermiscarriages.
Conclusion
The prevalenceo fm aternal thrombophiliasa nd adverse pregnancyoutcome has beendemonstrated to be influenced by factorsofethnicity,severity of diseaseand methods of testing. Important influencing factorsonthe severity of diseaseare the gestationalage at birth, growth restriction,hypertension, proteinuria and multiple adverse pregnancyo utcomes. This study has tried to address the knowledge of these aspects and thus to enhancethe prospect of uniformresearch in the future. We strongly suggest thatthe growing number of randomisedcontrolled trials on beneficial effect of low-molecular-weightheparin will carefuldescribe at leastthe threementionedconfounders: ethnicity, severity of diseaseand the genotype and phenotype of the thrombophiliaparameters,inrelation to anyadverse outcome of pregnancytoprevent premature introduction of treatment. 
